SNPMiner Trials (Home Page)
Report for Clinical Trial NCT04507919
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
The purpose of this Cohort Treatment Plan is to allow access to trametinib and dabrafenib for
eligible patients diagnosed with BRAF V600activating mutation-positive advanced NSCLC. The
patient's Treating Physician should follow the suggested treatment guidelines and comply with
all local health authority regulations.
Name: Dabrafenib and Trametinib
Description: The starting dose of the combination treatment will be administered as follows:
Dabrafenib, 150 mg, twice daily (BID);
Trametinib, 2.0 mg, once daily (QD)
Type: Drug
Name: Dabrafenib
Description: If a dose reduction below 50 mg BID for dabrafenib is required, dabrafenib will be permanently discontinued, but the patient will be allowed to continue trametinib.
Type: Drug
Name: Trametinib
Description: If a dose reduction below 1.0 mg once daily for trametinib is required, then trametinib will be permanently discontinued, but the patients will be allowed to continue dabrafenib.
Type: Drug
There is one SNP
SNPs
1 V600E
Stage IIIB, Stage IV) NSCLC (Non-Small Cell Lung Cancer) with confirmed BRAF
V600E/K activating mutation. --- V600E ---